Bruker (BRKR) Posts Quarterly Earnings Results

Bruker (NASDAQ:BRKR) issued its earnings results on Thursday. The medical research company reported $0.51 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.49 by $0.02, Bloomberg Earnings reports. Bruker had a return on equity of 25.83% and a net margin of 8.85%. The firm had revenue of $530.50 million for the quarter, compared to analyst estimates of $506.74 million. During the same period in the previous year, the company posted $0.46 earnings per share. The business’s revenue was up 12.8% on a year-over-year basis. Bruker updated its FY18 guidance to $1.34 to $1.38 EPS.

Bruker (BRKR) traded down $1.54 during trading on Thursday, reaching $31.62. The company had a trading volume of 1,040,000 shares, compared to its average volume of 484,321. Bruker has a twelve month low of $21.83 and a twelve month high of $36.53. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.60 and a current ratio of 2.60. The stock has a market capitalization of $4,920.00, a PE ratio of 33.64, a price-to-earnings-growth ratio of 2.50 and a beta of 1.05.

A number of research firms recently issued reports on BRKR. BTIG Research began coverage on Bruker in a research note on Friday, January 5th. They set a “buy” rating and a $42.00 price objective on the stock. Morgan Stanley reiterated an “equal weight” rating and set a $35.00 price objective on shares of Bruker in a research note on Thursday, December 14th. Zacks Investment Research upgraded Bruker from a “hold” rating to a “buy” rating and set a $39.00 price objective on the stock in a research note on Thursday, January 4th. BidaskClub lowered Bruker from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 11th. Finally, Evercore ISI began coverage on Bruker in a research note on Wednesday, January 3rd. They set an “in-line” rating and a $36.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and five have given a buy rating to the company’s stock. Bruker currently has a consensus rating of “Hold” and an average price target of $32.38.

A hedge fund recently raised its stake in Bruker stock. The Manufacturers Life Insurance Company raised its holdings in shares of Bruker Co. (NASDAQ:BRKR) by 7.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,003 shares of the medical research company’s stock after buying an additional 331 shares during the quarter. The Manufacturers Life Insurance Company ‘s holdings in Bruker were worth $144,000 as of its most recent filing with the Securities & Exchange Commission. 65.63% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This report was first reported by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.com-unik.info/2018/02/08/bruker-brkr-posts-quarterly-earnings-results.html.

About Bruker

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Earnings History for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit